Kidney Week

Abstract: FR-PO033

Contrast-Induced AKI and Adverse Clinical Outcomes Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

Session Information

• AKI: Clinical, Outcomes, Trials - I
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 102 AKI: Clinical, Outcomes, and Trials

Authors

• Yang, Yi, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, China

Yi Yang,

• Ge, Shuwang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Shuwang Ge,

• Xu, Gang, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, China

Gang Xu,

Background

Recent studies have shown associations between contrast-induced acute kidney injury (CI-AKI), in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), and increased risk of adverse clinical outcomes in ACS patients undergoing PCI; however, the estimates are inconsistent and vary widely.

Methods

EMBASE, PubMed, Web of Science^TM and Cochrane Library databases were systematically searched from inception to December 16, 2016 for cohort studies assessing the association between CI-AKI and any adverse clinical outcomes in ACS patients treated with PCI. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CI) of these outcomes. Heterogeneity was explored by subgroup analyses.

Results

We identified 1857 articles in electronic search, of which 23 (n=33080) were included. Our meta-analysis revealed that CI-AKI significantly increased the risk of all-cause mortality (18 studies; n= 28367; RR=3.16, 95% CI 2.52–3.97; I² =56.9%), short-term all-cause mortality (9 studies; n=13895; RR=5.55, 95% CI 3.53–8.73; I² =60.1%), major adverse cardiac event(7 studies; n=19841; RR=1.49, 95% CI: 1.34–1.65; I²=0), major adverse cardiovascular and cerebrovascular event (3 studies; n=2768; RR=1.86, 95% CI: 1.42–2.43; I²=0) and stent restenosis (3 studies; n=130678; RR=1.50, 95% CI: 1.24–2.81; I²=0), respectively, in ACS patients undergoing PCI. Subgroup analyses showed the study design, sample size and prevalence of CI-AKI might have effect on pooled RR.

Conclusion

CI-AKI may be a prognostic marker of adverse outcomes in ACS patients undergoing PCI. More attention should be paid to diagnosis and management of CI-AKI.